



18 August 2020

AIM: RENE

**ReNeuron Group plc**  
("ReNeuron" or the "Company")

**Posting of Annual Report and Accounts and Notice of AGM**

ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2020 and the Notice of the 2020 Annual General Meeting ("AGM") have been sent to shareholders and are also available on the Company's website at [www.reneuron.com](http://www.reneuron.com).

ReNeuron's AGM will be held at 10.00am on Thursday 10 September 2020 in the Company's offices at Pencoed Business Park, Pencoed, Bridgend CF35 5HY.

In light of the restrictions imposed due to the COVID-19 pandemic, the AGM this year will not be open for shareholders to attend in person. Shareholders are strongly advised to vote by proxy, further details of which are given in the Notice of AGM.

Shareholders are requested to send any questions for the Chairman to [info@reneuron.com](mailto:info@reneuron.com) at least 48 hours prior to the meeting. Where appropriate, such questions and answers will be collated and later published, together with full voting details, in the Investor Centre of the Company's website at [www.reneuron.com](http://www.reneuron.com).

**ENDS**

**ENQUIRIES:**

<b>ReNeuron</b> Olav Hellebø, Chief Executive Officer Michael Hunt, Chief Financial Officer	+44 (0) 20 3819 8400
<b>Buchanan</b> (Media/Investor relations) Mark Court, Tilly Abraham	+44 (0) 20 7466 5000
<b>Stifel Nicolaus Europe Limited</b> (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	+44 (0) 20 7710 7600
<b>N+1 Singer</b> (Joint Broker) Aubrey Powell, James Moat, Tom Salvesen	+44 (0) 20 7496 3000

**About ReNeuron**

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's clinical-stage candidates are in development

for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit [www.reneuron.com](http://www.reneuron.com).